NEWTOWN, Pa. — Shares of Traws Pharma collapsed on Monday, sinking to an all-time low after the small drugmaker said British regulators had blocked a key test of its experimental flu treatment. In a statement issued late Friday, June 12, the company said the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) had given a negative review to its planned mid-stage human study of tivoxavir marboxil, forcing the trial to be postponed.
The reaction was brutal. Traws Pharma stock fell about 17% in early Monday trading and dropped as much as 24% during the session, sliding to roughly $0.97 a share — a new 52-week low for a stock that traded as high as $3.27 over the past year. With limited Wall Street coverage, investors who do follow the company voted with their feet, wiping out a large chunk of its already small market value in a single morning.
Tivoxavir marboxil, the company’s lead drug, is a long-acting antiviral designed to treat and prevent influenza, including dangerous strains of bird flu. The blocked study was a human challenge trial, in which healthy volunteers would have received either the drug or a placebo and then been deliberately exposed to a controlled flu strain. That study was the centerpiece of the company’s near-term plans, and the regulator’s refusal leaves a major hole in its roadmap.
The British decision is especially painful because it follows a similar setback from the U.S. Food and Drug Administration. In February, the FDA placed a clinical hold on the company’s application to test the drug, citing concerns about mutagenicity — the potential of a substance to cause genetic mutations. With both the FDA and the MHRA now raising red flags, the path forward has narrowed sharply.
Traws Pharma is trying to reassure investors that the program still has life. “While we have had a setback in the development of our lead compound for influenza, the program continues to be a high priority,” said Dr. Robert Redfield, the company’s chief medical officer and former director of the Centers for Disease Control and Prevention.
Chief executive Iain Dukes said the feedback affects the timing of the study but not the company’s confidence in the science. He pointed to strong results in three animal models of bird flu and said the company has enough cash to operate into the first quarter of 2027 while advancing backup compounds designed to retain the original drug’s strengths without the mutagenicity concerns.
For a company of this size, timing and cash are everything. Traws Pharma raised up to $60 million in a private placement in April specifically to fund the now-postponed UK study — money raised for a trial that will not happen on schedule. Small clinical-stage drug developers typically have no products on the market and no sales. They survive on investor capital and the promise of future breakthroughs. When regulators halt a lead program, company value can disappear overnight.
Regulators such as the MHRA and FDA serve as gatekeepers between a laboratory discovery and a medicine patients can actually use. Their approval opens the door to testing and commercialization. Their objections can freeze a program, increase costs and force a company back to the drawing board.
For Traws Pharma, back-to-back regulatory setbacks in two countries have forced a strategic reset. The company’s hopes now rest increasingly on backup candidates that have yet to prove themselves in human testing.
The broader stakes extend beyond one stock. Long-acting flu treatments — particularly those that may be effective against bird flu — remain a significant public-health goal. But Monday’s plunge serves as a reminder of how fragile small biotechnology companies can be, and how quickly a regulatory decision thousands of miles away can erase years of investor optimism.
JBizNews Desk
© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.
